HomeCompareEVTZF vs JNJ

EVTZF vs JNJ: Dividend Comparison 2026

EVTZF yields 3.76% · JNJ yields 2.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JNJ wins by $10.1K in total portfolio value· pulled ahead in Year 6
10 years
EVTZF
EVTZF
● Live price
3.76%
Share price
$11.72
Annual div
$0.44
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.3K
Annual income
$0.38
Full EVTZF calculator →
JNJ
Johnson & Johnson
● Live price
2.14%
Share price
$242.49
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.5K
Annual income
$4,749.88
Full JNJ calculator →

Portfolio growth — EVTZF vs JNJ

📍 JNJ pulled ahead of the other in Year 6

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEVTZFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EVTZF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EVTZF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EVTZF
Annual income on $10K today (after 15% tax)
$319.95/yr
After 10yr DRIP, annual income (after tax)
$0.32/yr
JNJ
Annual income on $10K today (after 15% tax)
$182.28/yr
After 10yr DRIP, annual income (after tax)
$4,037.40/yr
At 15% tax rate, JNJ beats the other by $4,037.08/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EVTZF + JNJ for your $10,000?

EVTZF: 50%JNJ: 50%
100% JNJ50/50100% EVTZF
Portfolio after 10yr
$25.4K
Annual income
$2,375.13/yr
Blended yield
9.35%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

EVTZF
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
5.7
Piotroski
6/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-5.7% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EVTZF buys
0
JNJ buys
0
No recent congressional trades found for EVTZF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEVTZFJNJ
Forward yield3.76%2.14%
Annual dividend / share$0.44$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%28%
Portfolio after 10y$20.3K$30.5K
Annual income after 10y$0.38$4,749.88
Total dividends collected$380.00$15.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: EVTZF vs JNJ ($10,000, DRIP)

YearEVTZF PortfolioEVTZF Income/yrJNJ PortfolioJNJ Income/yrGap
1$10,888$188.21$10,594$274.49+$294.00EVTZF
2$11,746$95.76$11,294$360.69+$452.00EVTZF
3$12,617$48.27$12,133$476.91+$484.00EVTZF
4$13,524$24.23$13,156$635.42+$368.00EVTZF
5$14,483$12.14$14,432$854.61+$51.00EVTZF
6← crossover$15,503$6.07$16,056$1,162.76$553.00JNJ
7$16,591$3.04$18,175$1,604.53$1.6KJNJ
8$17,754$1.52$21,009$2,252.68$3.3KJNJ
9$18,997$0.76$24,911$3,229.73$5.9KJNJ
10$20,328$0.38$30,458$4,749.88$10.1KJNJ

EVTZF vs JNJ: Complete Analysis 2026

EVTZFStock

Evertz Technologies Limited engages in the design, manufacture, and distribution of video and audio infrastructure solutions for the production, post-production, broadcast, and telecommunications markets in Canada, the United States, and internationally. The company offers contribution encoder, decoder, receiver, processing, and modulation products; and control panels, unified controls, accessories, and network management systems. It also provides encoding, transcoding, and multiplexing products comprising ASI/IP converters, multiplexers, scramblers, and modulators; contribution encoders/decoders; transport stream processors; and software defined accelerated encoding/transcoding/muxing products, as well as audio/data/RF transporters, CWDM/DWDM multiplexors, fiber routers, SONET/SDH transporters, and video transporters. In addition, the company offers infrastructure and conversion products, including audio/data embedder/de-embedder, keyers, media and logo inserters, master control switchers, audio processing, closed captioning, conversion, audio/video delay system, distribution amplifier, and frame synchronizer products; and IP audio/video processing, media gateway, switch routing, timing, and software defined network orchestration products. Further, it provides 3D, auto changeover, film/post graticule generator, master clock/SPG, slave clock, test/reference generator, and timecode products for live media production; EMS media server, mediator content manager, and live integrated playout products; and multi viewers. Additionally, the company offers antennas, demodulators, fiber transporters, routers/switchers, and splitters and distribution amplifiers; and audio, bypass and auto changeover, data/LTC/tally, fiber/RF, magnum unified control, video routers, and panels. It serves content creators, broadcasters, specialty channels, and television service providers. The company was founded in 1966 and is headquartered in Burlington, Canada.

Full EVTZF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this EVTZF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EVTZF vs SCHDEVTZF vs JEPIEVTZF vs OEVTZF vs KOEVTZF vs MAINEVTZF vs ABBVEVTZF vs MRKEVTZF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.